IBT Receives Phase I SBIR grant from NIAID for development of neutralizing monoclonal antibodies against Marburg Virus
IBT in collaboration with the laboratory of Dr. Yuxing Li,
IBT Receives Phase II STTR grant from NIAID for development of Novel ISTAb therapeutics for B. anthracis
IBT in collaboration with Dr. Daniel Nelson’s lab at University
IBT Receives Phase I SBIR grant from NIAID for development of monoclonal antibodies against Marburg Virus using a novel discovery platform
IBT in collaboration with the laboratory of Dr. Brandon Dekosky,
IBT Receives Phase I/II Fast Track SBIR grant from NIAID for development of broadly protective monoclonal antibodies against Influenza Virus
IBT in collaboration with Abviro, LLC (Bethesda, MD) received a
IBT Receives Phase I SBIR grant from NIAID for development of Novel ISTAb therapeutics for Staph aureus
IBT in collaboration with Dr. Jean Lee lab at Brigham
IBT Receives Phase I SBIR grant from NIAID for development of rationally designed vaccines against multiple Ebolaviruses
IBT in collaboration with Integral Molecular (Philadelphia, PA) and US
Integrated Biotherapeutics Inc. Partners with CARB-X the first Toxoid based Multivalent Vaccine for MRSA
ROCKVILLE, Md., Nov. 1, 2017 /PRNewswire/ — Integrated Biotherapeutics Inc. announced
ExpreS2ion enters multi-product agreement with US-based Integrated BioTherapeutics for expansion of their commercial reagents portfolio
Hørsholm, Denmark, July 17, 2017 – Today, ExpreS2ion Biotech Holding
IBT Receives NIH R01 grant to study the mechanisms of ebolavirus vaccine protection
IBT Receives NIH R01 grant to study the mechanisms of
IBT Receives Phase II STTR from NIAID for development of Bispecific Antibodies against multiple Ebolaviruses
IBT Receives Phase II STTR from NIAID for development of
